{
    "ticker": "INSM",
    "name": "Insmed Incorporated",
    "description": "Insmed Incorporated is a biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. Founded in 1988 and based in Bridgewater, New Jersey, Insmed focuses on the development and commercialization of innovative therapies for patients with unmet medical needs. The company's lead product candidate, brensocatib, is an oral drug designed to treat patients with bronchiectasis, a chronic lung condition characterized by widening of the airways. Insmed's commitment to research and development is evident in its robust pipeline, which includes various programs aimed at addressing rare diseases associated with pulmonary and infectious conditions. The company emphasizes collaboration with patients, healthcare professionals, and researchers to bring forward new treatment options that improve quality of life and health outcomes. Insmed's mission is to pioneer a new era in the treatment of serious diseases, leveraging cutting-edge science and technology to make a meaningful difference in the lives of patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Bridgewater, New Jersey, USA",
    "founded": "1988",
    "website": "https://www.insmed.com",
    "ceo": "Will Lewis",
    "social_media": {
        "twitter": "https://twitter.com/Insmed",
        "linkedin": "https://www.linkedin.com/company/insmed-incorporated/"
    },
    "investor_relations": "https://investors.insmed.com",
    "key_executives": [
        {
            "name": "Will Lewis",
            "position": "CEO"
        },
        {
            "name": "Andrew D. Dorr",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Brensocatib"
            ]
        }
    ],
    "seo": {
        "meta_title": "Insmed Incorporated | Innovative Biopharmaceuticals for Rare Diseases",
        "meta_description": "Learn about Insmed Incorporated, a biopharmaceutical company focused on innovative therapies for serious and rare diseases. Explore our pipeline and commitment to patients.",
        "keywords": [
            "Insmed",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Brensocatib",
            "Pulmonary Conditions",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Insmed focus on?",
            "answer": "Insmed focuses on developing therapies for serious and rare diseases, particularly in the areas of pulmonary and infectious conditions."
        },
        {
            "question": "Who is the CEO of Insmed?",
            "answer": "Will Lewis is the CEO of Insmed Incorporated."
        },
        {
            "question": "Where is Insmed headquartered?",
            "answer": "Insmed is headquartered in Bridgewater, New Jersey, USA."
        },
        {
            "question": "What is Insmed's lead product candidate?",
            "answer": "Insmed's lead product candidate is brensocatib, aimed at treating bronchiectasis."
        },
        {
            "question": "When was Insmed founded?",
            "answer": "Insmed was founded in 1988."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "PTCT",
        "SAGE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "MRNA"
    ]
}